Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index fractionally up and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) rose 0.3%.
In corporate news, Novo Nordisk (NVO) has launched its weight-loss drug Wegovy in China, with the first prescription to be issued at a public hospital in Shanghai this week, China-based media outlet Yicai reported Monday, citing the Danish drugmaker's official WeChat account. Novo shares popped 3.1%.
Insmed (INSM) said Tuesday it terminated the sale agreement with Leerink Partners, effective Monday. Under the deal, the company agreed to offer and sell up to $500 million shares from time to time through Leerink as an agent. Insmed jumped past 9%.
EnVVeno Medical (NVNO) climbed 11.2% after the medical technology company said it had filed a premarket approval application with the US Food and Drug Administration for its VenoValve implants to treat severe chronic venous insufficiency.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。